154 Executive Equity Award Plan The Executive Equity Award Plan (EEAP) serves as a long-term incentive and is offered annually to the Board of Directors, the management Board, as well as other management levels of the <strong>Sonova</strong> Group. A total of approximately 400 people are participating in the 20<strong>11</strong> plan. The plan entitles them to receive shares, options, warrants, warrant appreciation rights (WARs), and/or restricted share units (RSUs). The number of shares, options, warrants, WARs, and RSUs granted varies depending on the respective management level and on individual performance. The shares, options, warrants, WARs, and RSUs granted as part of the EEAP are split into four equal tranches. The options, warrants and WARs have terms of five years. Each tranche vests each year, starting one year after the grant date. The strike price on which the options, warrants and WARs are based corresponds to the closing price for the shares on the Swiss stock exchange (SIX Swiss Exchange) on the date on which the options, warrants, and WARs were granted. The fair value of the options, warrants and WARs is calculated on the grant date using an option pricing model. The shares/RSUs have a blocking period of up to four years. One of the four equal tranches vests each year, starting one year after the grant date. Additional information can be found in Note 30 to the consolidated financial statements. Determination of the compensation to members of the Board of Directors The compensation policies for the Board of Directors differ from those for <strong>Sonova</strong> Group employees. The members of the Board of Directors receive a retainer and no variable cash compensation. The members of the Board of Directors also participate in the Executive Equity Award Plan. The compensation for the members of the Board of Directors is defined by the Nomination and Compensation Committee, periodically reviewed and set by the Board of Directors. Determination of the compensation to members of the management Board The compensation policies and the Executive Equity Award Plan (EEAP) described above apply to the CEO and the management Board. In management Board compensation, the variable salary component has a stronger weighting with respect to the target income than for other employees of the <strong>Sonova</strong> Group. The variable cash compensation varies between 30%–40% of the target salary for members of the management Board and 50% of the target salary for the former CEO. If a member of the management Board achieves less than 80% of the stipulated target, no variable salary component is paid out. If the target is exceeded, the variable cash compensation may be granted to a maximum of double the original amount, or for the former CEO, a maximum of 174%, depending on the actual level of achievement. The variable cash compensation is a function of company performance, based on sales, operating profit (EBITA) and individual achievement of objectives. The sales and EBITA targets are not interlinked. The Board of Directors can also award further cash components for exceptional achievements that do not fall under the annual objectives. The former CEO’s incentive plan differed in that the EEAP options were not granted to the former CEO annually in the last few years. The granting of options, including the period for exercising, was part of his employment contract.
COmPENSATION TO mEmBERS OF THE BOARD OF DIRECTORS AND THE mANAGEmENT BOARD FINANCIAL STATEmENTS OF SONOVA HOLDING AG 155 Compensation to the Board of Directors Total compensation to the Board of Directors consists of a fixed fee, attendance fees, expenses, social benefits (employer’s contribution), and participation in the Executive Equity Award Plan (solely with entitlement to receive options, warrants, WARs, and SARs). The following table shows the compensation of the individual members of the Board of Directors in the year under review and in the previous year: in CHF <strong>2010</strong>/<strong>11</strong> Fixed fee Attendance fee/expenses 1) Social benefits (employer’s contribution) 2) Total cash compensation Value of warrants 3) Number of warrants 3) granted Total compensation Robert F. Spoerry, Chairman4) 120,000 27,500 152,806 300,306 240,300 250,000 540,606 William D. Dearstyne, Vice-Chairman 120,000 30,000 320,122 470,122 240,300 250,0005) 710,422 Andy Rihs, member4) 120,000 31,000 188,790 339,790 240,300 250,000 580,090 Heliane Canepa, member 120,000 27,000 61,484 208,484 240,300 250,000 448,784 Dr Michael Jacobi, member 120,000 23,500 63,758 207,258 240,300 250,000 447,558 Anssi Vanjoki, member 120,000 15,500 25,715 161,215 240,300 250,000 401,515 Ronald van der Vis, member 120,000 14,500 25,539 160,039 240,300 250,000 400,339 John J. Zei, member6) 90,000 16,500 17,713 124,213 240,300 250,0005) 364,513 Total 930,000 185,500 855,927 1,971,427 1,922,400 2,000,000 3,893,827 1) Attendance fees and expenses are based on the number of attended meetings of each member of the Board of Directors. 2) Including social security contributions on the tax value of options/WARs/SARs exercised during the reporting period. 3) Exercise ratio between warrants and options: 25:1 (see also Note 30 in the consolidated financial statements). 4) Robert F. Spoerry took over the position as chairman of the Board of Directors from Andy Rihs in march 20<strong>11</strong>. 5) WARs (WARs grant the right to participate in the appreciation of the <strong>Sonova</strong> shares without issuance of shares). 6) New member of the Board of Directors since June <strong>2010</strong>. Dr Valentin Chapero Rueda received no compensation for his mandate as a member of the Board of Directors due to his mandate as CEO. in CHF 2009/10 Fixed fee Attendance fee/expenses 1) Social benefits (employer’s contribution) 2) Total cash compensation Value of warrants 3) Number of warrants 3) granted Total compensation Andy Rihs, Chairman 120,000 28,000 146,705 294,705 275,725 250,000 570,430 William D. Dearstyne, Vice-Chairman 60,000 28,000 <strong>11</strong>,2<strong>11</strong> 99,2<strong>11</strong> 275,725 250,0004) 374,936 Heliane Canepa, member 60,000 23,000 98,225 181,225 275,725 250,000 456,950 Dr Michael Jacobi, member 60,000 24,500 259,414 343,914 275,725 250,000 619,639 Robert F. Spoerry, member 60,000 22,500 204,642 287,142 275,725 250,000 562,867 Anssi Vanjoki, member 45,000 12,500 10,456 67,956 275,725 250,000 343,681 Ronald van der Vis, member 45,000 12,000 10,456 67,456 275,725 250,000 343,181 Total 450,000 150,500 741,109 1,341,609 1,930,075 1,750,000 3,271,684 1) Attendance fees and expenses are based on the number of attended meetings of each member of the Board of Directors. 2) Including social security contributions on the tax value of options/WARs/SARs exercised during the reporting period. 3) Exercise ratio between warrants and options: 25:1 (see also Note 30 in the consolidated financial statements). 4) WARs (WARs grant the right to participate in the appreciation of the <strong>Sonova</strong> shares without issuance of shares). Dr Valentin Chapero Rueda received no compensation for his mandate as a member of the Board of Directors due to his mandate as CEO.
- Page 1 and 2:
THE HEARING CARE COMPANY All the So
- Page 3 and 4:
highLightS & Key figureS - New sale
- Page 5 and 6:
02 Foreword 06 Sonova Group 16 Hear
- Page 7 and 8:
from 2002 to 2004 and subsequently
- Page 9 and 10:
eaKinG barrierS - with talent and t
- Page 11 and 12:
ON THE WAY TO BECOMING A GLOBAL HEA
- Page 13 and 14:
and a global distribution network e
- Page 15 and 16:
THE SONOVA GROUP No hearring loosss
- Page 17 and 18:
Better hearing for people with norm
- Page 19 and 20:
StraiGHt From real liFe - cowboy ha
- Page 21 and 22:
THE HEARING INSTRUMENT MARKET - CON
- Page 23 and 24:
THE PHONAK SPICE GENERATION - THE S
- Page 25 and 26:
WIDE RANGE OF HEARING INSTRUMENTS T
- Page 27 and 28:
LYRIC - THE “CONTACT LENS FOR THE
- Page 29 and 30:
Sonova is investing heavily in the
- Page 31 and 32:
Eight years later, Evelyn almost co
- Page 33 and 34:
THE HEARING IMPLANTS SEGMENT In the
- Page 35 and 36:
The considerable strategic importan
- Page 37 and 38:
ABOUT ADVANCED BIONICS Advanced Bio
- Page 39 and 40:
worKinG - and communicating safely
- Page 41 and 42:
EMPLOYEES FOCUS ON PEOPLE One of th
- Page 43 and 44:
ISO 9001:2000 and 13485:2003 certif
- Page 45 and 46:
The key environmental data shown in
- Page 47 and 48:
ENVIRONMENTAL MANAGEMENT AT THE ST
- Page 49 and 50:
CAMBODIA - BETTER OPPORTUNITIES FOR
- Page 51 and 52:
Better hearing - better success at
- Page 53 and 54:
in critical moments. As a consequen
- Page 55 and 56:
CrOSS-SHArEHOLDInGS Sonova Holding
- Page 57 and 58:
BOArD Of DIrECTOrS The primary duty
- Page 59 and 60:
Andy rihs Co-founder, non-executive
- Page 61 and 62:
onald van der Vis non-executive mem
- Page 63 and 64:
AuDIT COMMITTEE The members of the
- Page 65 and 66:
Alexander Zschokke Interim CEO, GVP
- Page 67 and 68:
Dr Hans Leysieffer GVP research & D
- Page 69 and 70:
COmPenSatiOn and SharehOldingS - co
- Page 71 and 72:
The shares/rSus have a blocking per
- Page 73 and 74:
COMPEnSATIOn TO MEMBErS Of THE MAnA
- Page 75 and 76:
SHArEHOLDInGS Of MEMBErS Of THE BOA
- Page 77 and 78:
The following table shows the detai
- Page 79 and 80:
CHAnGES Of COnTrOL AnD DEfEnSE MEAS
- Page 81 and 82:
COMPEnSATIOn rEPOrT inveStOrS at SO
- Page 83:
develOPing SPeeCh CaPaBilitieS - mo
- Page 86 and 87:
82 Financial Review - setting the c
- Page 88 and 89:
84 SALES in CHF m EBITA in CHF m 1,
- Page 90 and 91:
86 SUBSTANTIAl INVESTMENTS IN INNoV
- Page 92 and 93:
88 AdVANCEd BIoNICS RESUMES SAlES I
- Page 94 and 95:
90 5 year key Figures (Consolidated
- Page 96 and 97:
92 Consolidated Income Statements 1
- Page 98 and 99:
94 Consolidated Cash Flow Statement
- Page 100 and 101:
96 NoTeS To THe CoNSoLIdATed FINANC
- Page 102 and 103:
98 INveSTMeNTS IN JoINT veNTuReS In
- Page 104 and 105:
100 LeASING Assets that are held un
- Page 106 and 107:
102 SeGMeNT RePoRTING operating seg
- Page 108 and 109: 104 3.5 derivative financial instru
- Page 110 and 111: 106 3.7 Restatement of prior year
- Page 112 and 113: 108 Consolidated Changes in Equity
- Page 114 and 115: 110 5. segment information segment
- Page 116 and 117: 112 6. other expenses, net 1,000 ch
- Page 118 and 119: 114 Deferred tax assets and (liabil
- Page 120 and 121: 116 11. cash and cash equivalents 1
- Page 122 and 123: 118 14. other receivables and prepa
- Page 124 and 125: 120 the increase in property, plant
- Page 126 and 127: 122 1,000 cHf 31.3.2010 Cost Goodwi
- Page 128 and 129: 124 20. Provisions 1,000 cHf 31.3.2
- Page 130 and 131: 126 23. non-current financial liabi
- Page 132 and 133: 128 foreign currency sensitivity an
- Page 134 and 135: 130 the following table summarizes
- Page 136 and 137: 132 caPital RisK manaGement it is t
- Page 138 and 139: 134 the annual General shareholders
- Page 140 and 141: 136 28. Related party transactions
- Page 142 and 143: 138 Amounts recognized in the incom
- Page 144 and 145: 140 30. Employee share option and s
- Page 146 and 147: 142 The fair value of options/warra
- Page 148 and 149: 144 Changes in outstanding shares/R
- Page 150 and 151: 146 36. list of significant consoli
- Page 152 and 153: 148 REPORT OF THE STATuTORY AuDITOR
- Page 154 and 155: 150 Income Statements 1,000 CHF Not
- Page 156 and 157: 152 NOTES TO THE FINANCIAL STATEmEN
- Page 160 and 161: 156 Compensation to the management
- Page 162 and 163: 158 The following table shows the d
- Page 164 and 165: 160 Warrants EEAP 10 2) Warrants/ o
- Page 166 and 167: 162 Company name Activity Domicile
- Page 168 and 169: 164 Appropriation of Available Earn
- Page 170 and 171: 166 REPORT OF THE STATUTORy AUDITOR
- Page 173 and 174: Disclaimer This report contains for